Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial (2015)
- Authors:
- Autor USP: NICOLAU, JOSÉ CARLOS - FM
- Unidade: FM
- DOI: 10.2337/dc14-1850
- Subjects: DIABTES MELLITUS (COMPLICAÇÕES); FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO; INIBIDORES DE ENZIMAS; NEOPLASIAS (ETIOLOGIA)
- Language: Inglês
- Imprenta:
- Publisher place: Alexandria
- Date published: 2015
- Source:
- Título do periódico: Diabetes Care
- ISSN: 0149-5992
- Volume/Número/Paginação/Ano: v. 38, n. 4, p. 696-705, 2015
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: bronze
-
ABNT
UDELL, Jacob A. et al. Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial. Diabetes Care, v. 38, n. 4, p. 696-705, 2015Tradução . . Disponível em: https://doi.org/10.2337/dc14-1850. Acesso em: 30 set. 2024. -
APA
Udell, J. A., Bhatt, D. L., Braunwald, E., Cavender, M. A., Mosenzon, O., Steg, G., et al. (2015). Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial. Diabetes Care, 38( 4), 696-705. doi:10.2337/dc14-1850 -
NLM
Udell JA, Bhatt DL, Braunwald E, Cavender MA, Mosenzon O, Steg G, Davidson JA, Nicolau JC, Corbalan R, Hirshberg B, Frederich R, Im KA, Umez-Eronini AA, He P, McGuire DK, Leiter LA, Raz I, Scirica BM. Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial [Internet]. Diabetes Care. 2015 ; 38( 4): 696-705.[citado 2024 set. 30 ] Available from: https://doi.org/10.2337/dc14-1850 -
Vancouver
Udell JA, Bhatt DL, Braunwald E, Cavender MA, Mosenzon O, Steg G, Davidson JA, Nicolau JC, Corbalan R, Hirshberg B, Frederich R, Im KA, Umez-Eronini AA, He P, McGuire DK, Leiter LA, Raz I, Scirica BM. Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial [Internet]. Diabetes Care. 2015 ; 38( 4): 696-705.[citado 2024 set. 30 ] Available from: https://doi.org/10.2337/dc14-1850 - Ticagrelor versus clopidogrel in patients with STEMI treated with fibrinolysis TREAT trial
- Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial (vol 3, pg 391, 2018)
- Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial
- Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF
- Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial
- Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry
- Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54
- Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries
- Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial
- Rationale and design of the long-Term rIsk, clinical manaGement, and healthcare Resource utilization of stable coronary artery dISease in post-myocardial infarction patients (TIGRIS) study
Informações sobre o DOI: 10.2337/dc14-1850 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
